"Alliance for Multispecialty Research was founded in 1994 and became AMR in 2017 with sixteen locations throughout the United States – fourteen fully-owned research centers and two affiliate centers. We are built on relationships with sponsors, physicians, CROs, pharmaceutical companies and our clinical research volunteers. We are backed by results. Accurate, precise, powerful, timely results that advance medicine. We know that clinical research matters. And we have the results to prove it."

During the past decade, Alliance for Multispecialty Research, LLC conducted 26 clinical trials. In the 10-year time frame, 26 clinical trials started and 3 clinical trials were completed, i.e. on average, 11.5% percent of trials that started reached the finish line to date. In the past 5 years, 25 clinical trials started and 3 clinical trials were completed. i.e. 12% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Alliance for Multispecialty Research, LLC" #1 sponsor was "Pfizer" with 4 trials, followed by "Achieve Life Sciences" with 2 trials sponsored, "Concert Pharmaceuticals" with 2 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored and "Emergent BioSolutions" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Alliance for Multispecialty Research, LLC" #1 collaborator was "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Department of Health and Human Services" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator, "Ionis Pharmaceuticals, Inc." with 1 trials as a collaborator and "National Institute of Allergy and Infectious Diseases (NIAID)" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Alliance for Multispecialty Research, LLC" are "COVID-19" (3 trials), "Chikungunya Virus Infection" (2 trials), "Hepatic Impairment" (2 trials), "Pharmacokinetics" (2 trials) and "SARS-CoV-2 Infection" (2 trials). Many other conditions were trialed in "Alliance for Multispecialty Research, LLC" in a lesser frequency.

Most popular intervention types in "Alliance for Multispecialty Research, LLC" are "Drug" (15 trials), "Biological" (11 trials), "Other" (3 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (13 trials), "BNT162b2" (2 trials), "Behavioral support" (2 trials), "CTP-543" (2 trials) and "MDMA" (2 trials). Other intervention names were less common.

The vast majority of trials in "Alliance for Multispecialty Research, LLC" are 25 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Alliance for Multispecialty Research, LLC". 2 are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Alliance for Multispecialty Research, LLC, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Alliance for Multispecialty Research, LLC, 11 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".